Cooley LLP is an international law firm that advises companies, investors, and boards on corporate, regulatory, and litigation matters. The firm’s practice covers mergers and acquisitions, capital markets, private financings, licensing and collaborations, intellectual property counseling and enforcement, antitrust, employment, investigations, and complex disputes. Cooley serves clients across the innovation economy, with notable depth in technology, life sciences, healthcare, and venture capital. The firm operates across the United States, Europe, and Asia.
For chemical and life sciences stakeholders, Cooley provides counsel on transactions, IP strategy and protection, product and safety regulation, FDA- and EMA-related matters, supply and manufacturing agreements, data and privacy issues, corporate governance, and cross‑border deal execution. Its experience spans public and private company work, from early-stage financings through IPOs and post‑market compliance, as well as strategic M&A and partnerships involving biotech, pharma, medical devices, diagnostics, and specialty materials companies.
Lead program in Phase 1; POC data due late 2026. Designed to deliver deeper, more durable responses than current Type I JAK2 therapies. Deal may pay up to $2.3B, subject to closing.
Lilly's tender offer for Adverum shares expired, with 64% tendered. Acquisition completion expected Dec. 9, 2025. Legal and financial advisors involved.